Facebook
Twitter
LinkedIn
Forward2025 Nebraska Congress on Hematologic Malignancies: Recent Advances and Cellular Therapy
Overview
The 2025 Nebraska Congress on Hematologic Malignancies: Recent Advances and Cellular Therapy is a one-day CME-accredited, in-person conference that convenes leading experts to discuss the latest advances in the management of benign and malignant hematologic disorders. This program emphasizes a multidisciplinary approach to integrating emerging therapies into clinical practice, including CAR T-cell therapy, bispecific antibodies, and gene therapies, to enhance patient-centered care.
Targeted at physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals, this conference features expert-led lectures, case-based presentations, and panel discussions. Participants will gain a deeper understanding of the efficacy, safety, and application of novel therapies, as well as strategies to address barriers to care and optimize clinical outcomes.
The conference provides a unique opportunity for attendees to engage with key opinion leaders and peers, fostering collaborative discussions on practice-changing data and expert recommendations. Through the integration of recent advances into patient care, this activity aims to strengthen healthcare providers’ knowledge, competence, and decision-making in managing hematologic malignancies.
Target Audience
- Hematologists/Oncologists
- Oncology Nurse Practitioners
- Oncology Pharmacists
- Oncology Physician Assistants
- Oncology Fellows/Residents
- Oncology Nurses
- Researchers and others involved in the care of cancer patients
Organizing Committee
Conference Director:
- Binay Shah, MD, MHA - Binaytara
Conference Chairs:
- Christopher D'Angelo, MD - University of Nebraska Medical Center
- Krishna Gundabolu, MD, MS, FACP - University of Nebraska Medical Center
- Joel Michalski, MD, PhD - Nebraska Cancer Specialists
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for initial and relapsed therapy in benign and malignant hematologic disorders.
- Outline efficacy and toxicity profiles of emerging and approved therapies, including small molecules, monoclonal antibodies, bispecifics, ADCs, CAR T-cell therapies, and gene therapies.
- Apply individualized treatment plans based on patient characteristics, disease factors, and therapeutic advancements.
- Identify barriers to accessing innovative therapies and develop strategies to address financial, logistical, and systemic challenges.
Hotel Room Reservation
A limited number of guestrooms are reserved at the Hilton Omaha for the participants of this meeting at a discounted rate of $154 per night. The room rate does not include any additional fees or applicable taxes.
Parking
- Daily Self-Parking: $5 per hour with a daily maximum of $35
- Overnight Self-Parking: $29.00 per-day
- Overnight Valet Parking: $40 per-day
Program
Saturday, April 12, 2025
All times below are listed in Central Daylight Time (CDT).
07:00 AM – 08:00 AM Registration, Breakfast, & Exhibits
08:00 AM – 08:05 AM Welcome
08:05 AM – 08:30 AM Binaytara's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA
08:30 AM – 09:40 AM Session 1: Acute Myeloid Leukemia and Myeloproliferative Neoplasms
Session Chair: Steven Dunder, MD
08:30 AM – 08:50 AM Induction Strategies for Fit and Frail Acute Myeloid Leukemia - Michael Haddadin, MD
08:50 AM – 09:10 AM Targeted Agents for Relapsed and Refractory AML - Stacey Knox, MD
09:10 AM – 09:30 AM Best Practice for Newly Diagnosed ET and PV - Peter T. Silberstein, MD
09:30 AM – 09:40 AM Q & A
09:40 AM – 10:10 AM Break & Exhibits
10:10 AM – 11:20 AM Session 2: Lymphoma
Session Chair: Mehmet Sitki Copur, MD, FACP
10:10 AM – 10:30 AM Best Strategy for Newly Diagnosed Hodgkin Lymphoma - Christopher D'Angelo, MD
10:30 AM – 10:50 AM Initiation of Bispecific Antibody Therapy for Relapsed DLBCL - Kailash Mosalpuria, MD, MPH, FACP
10:50 AM – 11:10 AM The Who, What, When, Where and Why of CAR T Cell Therapy for Non-Hodgkin Lymphoma in 2024 - Snegha Ananth, MBBS, MD
11:10 AM – 11:20 AM Q & A
11:20 AM – 12:20 PM Lunch & Exhibits
Product Theater Sponsored by Johnson & Johnson
Title: TECVAYLI Overview & DARZALEX FASPRO PERSEUS TRIAL | Speaker: Dr. Leo Shuhyakov
* This is a non-CME activity*
12:20 PM – 01:10 PM Session 3: Multiple Myeloma
Session Chair: Soe Min Tun, MD, MBA, MSc, PhD
12:20 PM – 12:40 PM Management and Induction Strategies for Newly Diagnosed Multiple Myeloma - Eric J. Avery, MD
12:40 PM – 01:00 PM Transplant and Maintenance in Multiple Myeloma - Timothy Dorius, MD
01:00 PM – 01:10 PM Q & A
01:10 PM – 01:40 PM Break & Exhibits
01:40 PM – 02:50 PM Session 4: Classical Hematology and Real-World Challenges in Hematologic Malignancies
Session Chair: Marcel P. Devetten, MD
01:40 PM – 02:00 PM Gene Therapies for Hemophilia and Hemoglobinopathies - Alex Nester, MD
02:00 PM – 02:20 PM Palliative Care and Hematologic Malignancies - Kathleen McKillip, MD
02:20 PM – 02:50 PM Q & A
02:50 PM Adjourn
Venue
Parking
- Daily Self-Parking: $5 per hour with a daily maximum of $35
- Overnight Self-Parking: $29.00 per-day
- Overnight Valet Parking: $40 per-day
Faculty
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Christopher D'Angelo, MD
Krishna Gunbabolu, MD; MS; FACP
Joel Michalski, MD PhD
Mehmet Copur, MD FACP
Marcel Devetten
Steven Dunder, MD
Peter Silberstein
SOE MIN TUN, MBBS, PhD, FACP
Snegha Ananth, MD
Eric Avery, MD
Timothy Dorius, MD
Michael Haddadin, MBBS, MS
Stacey Knox
Kathleen McKillip, MD
Kailash Mosalpuria, MD, MPH, FACP
Alex Nester, MD
Accreditation
Acknowledgement of Commercial Support
This activity is supported with an Independent Medical Education grant from Genentech.
Available Credit
- 4.25 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 4.25 ACPE Pharmacy
The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-008-L01-P
Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.
The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.
After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.
- 4.25 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 4.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 4.25 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 4.25 Contact Hours.
Exhibitors
If you are interested in exhibiting at this meeting or purchasing a badge with your company at our discounted rate for exhibitors, please visit our exhibit page here - https://www.sponsorships.binayfoundation.org/OmahaHematology
Register/Take course
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.